C12N 2320/34
Allele or polymorphism specific uses
C12N2320/34 (Allele or polymorphism specific uses) appears on 204 US grants and 562 published applications in this corpus.
Search patents in C12N- Granted patents
- 204
- Published applications
- 562
- Assignees
- 237
- Inventors
- 1,051
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 3 |
| 2010 | 0 | 0 |
| 2011 | 0 | 5 |
| 2012 | 0 | 3 |
| 2013 | 1 | 8 |
| 2014 | 3 | 16 |
| 2015 | 9 | 15 |
| 2016 | 5 | 11 |
| 2017 | 10 | 28 |
| 2018 | 11 | 21 |
| 2019 | 18 | 23 |
| 2020 | 17 | 44 |
| 2021 | 16 | 57 |
| 2022 | 19 | 64 |
| 2023 | 29 | 68 |
| 2024 | 24 | 85 |
| 2025 | 26 | 64 |
| 2026 | 16 | 46 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- RNA G-quadruplex structure in pre-miRNA-1229 as a therapeutic target for Alzheimer's disease and various cancers11 Aug 2026US 12,703,863 B2Duquesne University of the Holy Spirit
- RNAI constructs for inhibiting PNPLA3 expression and methods of use thereof7 Jul 2026US 12,674,166 B2Amgen Inc.
- Compositions and methods for editing beta-globin for treatment of hemaglobinopathies16 Jun 2026US 12,653,860 B2Vertex Pharmaceuticals Incorporated
- Systems, methods, and compositions for targeted nucleic acid editing16 Jun 2026US 12,655,403 B2
- Pyruvate kinase deficiency (PKD) gene editing treatment method16 Jun 2026US 12,655,406 B2Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A, M.P.
- Compositions and methods to modulate idiopathic pulmonary fibrotic associated long noncoding rnas24 Sep 2026US 2026/0286360 A1HAYA Therapeutics SA
- Fah-modulating compositions and methods3 Sep 2026US 2026/0258424 A1Flagship Pioneering Innovations VI, LLC
- Engineered trna and methods of use27 Aug 2026US 2026/0248838 A1The University of Chicago
- Compositions for treating cancer with kras mutations and uses thereof27 Aug 2026US 2026/0248963 A1Aadigen, LLC
- Treatment Of Glaucoma With Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) Inhibitors27 Aug 2026US 2026/0250681 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Selective reduction of allelic variants40US 8,957,040 B2Isis Pharmaceuticals, Inc. · 2015
- siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)33US 10,526,605 B2Purdue Research Foundation · 2020
- Modulation of gene expression and screening for deregulated protein expression28US 10,196,639 B2University of Southampton · 2019
- Methods and compositions for the treatment of Huntington'S disease27US 8,679,750 B2The University of British Columbia · 2014
- RNA interference for the treatment of gain-of-function disorders27US 8,680,063 B2University of Massachusetts · 2014